Peter Hovstadius

Chief Tech/Sci/R&D Officer at LIPUM AB

Health Technology

Consumer Services

Profile

Peter Hovstadius currently works at Lipum AB, as Chief Medical Officer from 2024.
Dr. Hovstadius also formerly worked at Merck Sharp & Dohme AB, as Research Director, XNK Therapeutics AB, as Chief Medical Officer, and Novartis Sverige AB, as Chief Scientific Officer.
Dr. Hovstadius received his doctorate degree from the University of Uppsala.

Peter Hovstadius active positions

Companies	Position	Start
LIPUM AB	Chief Tech/Sci/R&D Officer	19/08/2024

All active positions of Peter Hovstadius

Former positions of Peter Hovstadius

Companies	Position	End
Novartis Sverige AB Novartis Sverige AB Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical, ophthalmic and generic drugs	Chief Tech/Sci/R&D Officer	-
Merck Sharp & Dohme AB	Chief Tech/Sci/R&D Officer	-
CellProtect Nordic Pharmaceuticals AB CellProtect Nordic Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Develops cell-based therapies for treatment of severe diseases	Chief Tech/Sci/R&D Officer	-

See the detail of Peter Hovstadius's experience

Training of Peter Hovstadius

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Peter Hovstadius's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	5
University of Uppsala University of Uppsala Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Novartis Sverige AB Novartis Sverige AB Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical, ophthalmic and generic drugs	Health Technology
CellProtect Nordic Pharmaceuticals AB CellProtect Nordic Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Develops cell-based therapies for treatment of severe diseases	Health Technology
Lipum AB Lipum AB BiotechnologyHealth Technology Develops biological anti-inflammatory drugs	Health Technology
Merck Sharp & Dohme AB